Fig. 2

Allo-HSCT overcame the adverse prognosis of low miR-425 expression in AML.a, b A total of 162 patients were divided into two groups based on the median expression levels of miR-425. Kaplan–Meier survival curves of patients with respect to chemotherapy (n = 40) and allo-HSCT (n = 41) treatment in the low-miR-425-expression group. c, d Kaplan–Meier survival curves of patients with respect to chemotherapy (n = 50) and allo-HSCT (n = 31) treatment in the high-miR-425-expression group